Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10484531 | 0.85 | TSHR (0.67) | TSHRCA1CA2RAB9AMAPT | |
| SCHEMBL9340188 | 0.85 | TSHR (0.67) | TSHRCA1CA2RAB9AMAPT | |
| SCHEMBL33494 | 0.85 | LOXL2 (0.66) | TSHRCES2CES1LOXL2CA1 | |
| SCHEMBL1509563 | 0.85 | TSHR (0.53) | TSHRLOXL2CA1CA2RAB9A | |
| Toluene SCHEMBL27262094 | 0.84 | TDP1 (0.59) | TSHRCES2CES1LOXL2CA1 | |
| SCHEMBL9875461 | 0.84 | LOXL2 (0.56) | TSHRLOXL2RAB9AMAPTCYP4A11 | |
| SCHEMBL4050879 | 0.84 | LOXL2 (0.63) | TSHRCES2CES1LOXL2CA1 | |
| Bromide SCHEMBL4809006 | 0.84 | LOXL2 (0.63) | TSHRCES2CES1LOXL2CA1 | |
| Methyl Benzoate SCHEMBL28154074 | 0.84 | TSHR (0.76) | TSHRCA1CA2RAB9AMAPT | |
| SCHEMBL27262281 | 0.82 | MGLL (0.56) | TSHRCES2CES1LOXL2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2020-07-23 | — | — | US | disclosed |
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3599236-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2020-01-29 | — | — | EP | disclosed |
| EP-3202460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| EP-3106460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-0819107-A1 | 9-SUBSTITUTED PORPHYCENES | CYTOPHARM, INC. (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5661178-A | Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives | ALLERGAN (US) | 1997-08-26 | — | — | US | disclosed |
| US-5637608-A | PHOTODYNAMIC THERAPY | CYTOPHARM, INC. (US) | 1997-06-10 | — | — | US | disclosed |
| WO-1997018207-A2 | NOVEL MACROCYCLIC COMPOUNDS AS METALLOPROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| WO-1997009049-A2 | METHOD FOR EFFECTING VASODILATION WITH (1,5-INTER)ARYL PROSTAGLANDIN DERIVATIVES | ALLERGAN (US) | 1997-03-13 | — | — | WO | disclosed |
| US-5610175-A | 9-Substituted porphycenes | CYTOPHARM, INC. (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996031451-A1 | 9-SUBSTITUTED PORPHYCENES | CYTOPHARM, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996031452-A1 | 9-SUBSTITUTED PORPHYCENES | CYTOPHARM, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | TSHR 2970/4885CES2 178/4885CES1 432/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | TSHR 2970/4885CES2 178/4885CES1 432/4885 |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | TSHR 2970/4885CES2 178/4885CES1 432/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | TSHR 2970/4885CES2 178/4885CES1 432/4885 |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | TSHR 2970/4885CES2 178/4885CES1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.